MannKind Q1 2023 revenues jump 239% to $41M; loss from ops down 72%

MANNKIND CORP

2023-Q1 EPS reported -$0.04 revenue$40,626,000

Total revenues $40.6M, +239% vs Q1 2022; Tyvaso DPI contributed $23M (services + royalties).
Afrezza net revenue $12.4M (+26% YoY); V-Go added $5.1M after Q2 2022 acquisition.
Loss from operations narrowed 72% to $6M; commercial product gross margin 69%.
Cash and investments $166.6M at March 31, 2023; R&D spend up to $5.6M for pipeline.
CEO cites strong Tyvaso DPI demand; Phase 2/3 inhaled clofazimine trial planned H2 2023.

item 9.01 item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.

Period: the quarter ended March 31, 2023
Revenue: $41 million
Result: reported results

Exact text from the filing

1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022

View on SEC.gov

Browse all earnings releases →

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-019977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.